PARK25 (PTPA-Related Parkinsonism): A Patient Guide
At a Glance
PARK25 is an ultra-rare inherited condition caused by harmful changes in the PPP2R4 gene. It combines parkinsonism—stiffness, slowed movement, and tremor that often begin in adolescence—with intellectual disability; some people respond to carefully monitored levodopa.
PARK25, also known as PTPA-related parkinsonism, is an ultra-rare genetic condition that, in the reported individuals, typically begins to show its physical signs during the teenage years. For many families, receiving this diagnosis is the end of a long “diagnostic odyssey,” providing a name for a complex set of symptoms that include both movement challenges and intellectual disability. While the condition is lifelong, understanding its genetic cause—pathogenic variants in the PPP2R4 gene (formerly known as PTPA)—allows for a more targeted approach to care and helps distinguish it from other conditions that may look similar but require different treatments [1][2].
What is Known and What is Still Uncertain
Because PARK25 has been reported in only a few families worldwide as of recently, its natural history remains uncertain. Care must be highly individualized, and the observations below are based on limited case reports, not broad population studies.
The condition involves motor and neurodevelopmental features. The movement symptoms, known as parkinsonism, often involve muscle stiffness, slowness of movement, and tremors that emerge in adolescence. At the same time, individuals with PARK25 live with a foundational intellectual disability that is usually present from early childhood. Unlike some other neurodegenerative diseases, the cognitive challenges in reported individuals tend to remain relatively stable over time, rather than following a path of rapid decline [1].
One of the most encouraging aspects of PARK25 is that the motor symptoms in some reported individuals have shown a “marked and sustained” response to a carefully monitored trial of levodopa, a standard medication used to manage Parkinson’s symptoms. This means that while the underlying genetic mutation cannot yet be fixed, some of the physical challenges may be managed medically. However, benefit and adverse effects vary, and response should not be used alone for prognosis. Because the condition is so rare, a specialized, multidisciplinary care team is essential to balance medication and supportive therapies [1][2].
Whether you are the diagnosed person or a caregiver, your observations are a vital part of the medical record. Because PARK25 affects each person differently, your partnership with specialists in movement disorders and genetics is the key to navigating the road ahead. While a diagnosis of an ultra-rare condition is significant, it also provides a roadmap for support, connecting you to a growing global understanding of this specific genetic pathway and the treatments that help manage it [1].
In this guide
6 chapters
Understanding PARK25 (PPP2R4-Related Parkinsonism)
Learn about PARK25, a PPP2R4-related parkinsonism with intellectual disability, including symptoms, autosomal recessive inheritance, diagnosis, and treatment.
Recognizing and Managing PARK25 Symptoms
Learn to recognize PARK25 motor, cognitive, and swallowing symptoms, understand levodopa side effects, and know which changes require prompt or emergency care.
The Science of PARK25: The PPP2R4 Gene
Learn how PPP2R4 variants cause PARK25, how autosomal recessive inheritance works, and which genetic report findings help confirm a diagnosis in practice.
Treating and Supporting Someone with PARK25
Learn how PARK25 is treated with levodopa, DBS, and supportive therapies, while managing dyskinesia, medication risks, intellectual disability, and daily care.
Building Your Care Team and Preparing for Visits
Learn how to build a PARK25 care team, prepare genetic and medical records, record useful home videos, and ask focused questions at movement-disorder visits.
Navigating Daily Life with PARK25
Learn how people with PARK25 can promote mobility and independence through therapy, swallowing safety, education plans, caregiver support, and respite care.
Common questions in this guide
What is PARK25, and what causes it?
What symptoms usually appear with PARK25?
Can levodopa help with PARK25 movement symptoms?
Does intellectual disability change how PARK25 is treated?
Which specialists should be involved in PARK25 care?
How certain is what doctors know about PARK25’s long-term course?
How might a PPP2R4 diagnosis change treatment compared with a general Parkinson’s diagnosis?
Get notified when new evidence is published on Parkinson disease 25, autosomal recessive early-onset, with impaired intellectual development.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (2)
- 1
PTPA variants and impaired PP2A activity in early-onset parkinsonism with intellectual disability.
Fevga C, Tesson C, Carreras Mascaro A, et al.
Brain : a journal of neurology 2023; (146(4)):1496-1510 doi:10.1093/brain/awac326.
PMID: 36073231 - 2
Cross-Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease.
Li C, Lin J, Jiang Q, et al.
Movement disorders : official journal of the Movement Disorder Society 2023; (38(6)):1099-1104 doi:10.1002/mds.29411.
PMID: 37046398
This page is for informational purposes only and does not constitute medical advice about PARK25. A movement-disorders specialist and genetics team can interpret the diagnosis and tailor treatment for the individual.